Michael J. McElhaugh Net Worth

The estimated Net Worth of Michael J. Mc Elhaugh is at least $7.89 million dollars as of 1 February 2024. Mr Elhaugh owns over 10,164 units of Arbutus Biopharma Corp stock worth over $6,861,856 and over the last 6 years he sold ABUS stock worth over $423,679. In addition, he makes $603,425 as Chief Bus. Officer at Arbutus Biopharma Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr McElhaugh ABUS stock SEC Form 4 insiders trading

Mr has made over 4 trades of the Arbutus Biopharma Corp stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 10,164 units of ABUS stock worth $23,479 on 1 February 2024.

The largest trade he's ever made was selling 40,000 units of Arbutus Biopharma Corp stock on 14 December 2020 worth over $200,000. On average, Mr trades about 10,018 units every 143 days since 2019. As of 1 February 2024 he still owns at least 1,504,793 units of Arbutus Biopharma Corp stock.

You can see the complete history of Mr Elhaugh stock trades at the bottom of the page.

Mr. Michael J. McElhaugh biography

Michael J. McElhaugh is the Chief Bus. Officer at Arbutus Biopharma Corp.

What is the salary of Mr McElhaugh?

As the Chief Bus. Officer of Arbutus Biopharma Corp, the total compensation of Mr McElhaugh at Arbutus Biopharma Corp is $603,425. There are 3 executives at Arbutus Biopharma Corp getting paid more, with William H. Collier having the highest compensation of $972,317.

How old is Mr McElhaugh?

Mr McElhaugh is 47, he's been the Chief Bus. Officer of Arbutus Biopharma Corp since . There are 8 older and no younger executives at Arbutus Biopharma Corp. The oldest executive at Arbutus Biopharma Corp is R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C, Q.C., 70, who is the Sec..

What's Mr McElhaugh's mailing address?

Michael's mailing address filed with the SEC is C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER, PA, 18974.

Insiders trading at Arbutus Biopharma Corp

Over the last 10 years, insiders at Arbutus Biopharma Corp have traded over $2,165,982 worth of Arbutus Biopharma Corp stock and bought 1,000 units worth $6,950 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ... et Andrew Lo. On average, Arbutus Biopharma Corp executives and independent directors trade stock every 164 days with the average trade being worth of $124,173. The most recent stock trade was executed by Keith S Manchester on 14 August 2024, trading 54,915 units of ABUS stock currently worth $30,752.

What does Arbutus Biopharma Corp do?

arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the hbv treatment landscape and cure hepatitis b virus disease. in addition to our hbv assets, we are developing a pipeline of programs that leverage our expertise in rna interference (rnai) therapeutics and our lipid nanoparticle (lnp) technology.

Complete history of Mr Elhaugh stock trades at Arbutus Biopharma Corp

Arbutus Biopharma Corp executives and stock owners

Arbutus Biopharma Corp executives and other stock owners filed with the SEC include:

• William H. Collier,
  Pres, CEO & Director
• Dr. Michael J. Sofia Ph.D.,
  Chief Scientific Officer
• Dr. Michael J. Sofia,
  Chief Scientific Officer
• Michael J. McElhaugh,
  Chief Bus. Officer
• R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C, Q.C.,
  Sec.
• Lisa M. Caperelli,
  VP of Investor Relations
• R. Hector Mackay-Dunn B.A., L.L.B., Q.C., J.D., Q.C,
  Sec.
• Dr. Gaston Picchio Ph.D.,
  Chief Devel. Officer
• Dr. Elizabeth Howard,
  Exec. VP, Gen. Counsel, Chief Compliance Officer & Sec.
• Pam Murphy,
  Investor Relations Consultant
• David C. Hastings,
  CFO & Chief Accounting Officer
• Keith S Manchester,
  Director
• Frank Karbe,
  Director
• Richard C Jr Henriques,
  Director
• Herbert J Conrad,
  Director
• Daniel D Burgess,
  Director
• William T. Symonds,
  Chief Development Officer
• Vivek Ramaswamy,
  Director
• Michael J. Sofia,
  Chief Scientific Officer
• Patrick T. Higgins,
  Chief Business Officer
• Mark Kowalski,
  Sr VP & Chief Medical Officer
• Michael J. Abrams,
  Exec. VP & Chief Discovery Off
• Mark J. Murray,
  President & CEO
• Peter Lutwyche,
  Chief Tech. Operations Officer
• J. Christopher Naftzger,
  General Counsel and CCO
• Karen Sims,
  Chief Medical Officer
• Bruce Cousins,
  Exec VO & CFO
• Associates Gp Llcqvt Fund V...,
  
• Sciences Ltd. Roivant,
  10% owner
• Holdings Ltd.Dexcel Pharma ...,
  
• Investments (Uk) Ltd Soft B...,
  
• Global Investors Lp Viking ...,
  
• Global Performance Llc Viki...,
  
• Patrick Machado,
  
• Koert Vanden Enden,
  Chief Accounting Officer
• Melissa Rewolinski,
  Director
• David C Hastings,
  Chief Financial Officer
• Gaston Picchio,
  Chief Development Officer
• Myrtle S Potter,
  Director
• James R Meyers,
  Director
• Frank Torti,
  Director
• William H. Collier,
  President and CEO
• Global Performance Llc Viki...,
  
• Andrew Cheng,
  Director
• Tram Tran,
  Director
• Elizabeth Howard,
  EVP, GC, Compliance
• Michael J. Mc Elhaugh,
  Interim President & CEO